Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization
Abstract Parkinson’s disease (PD) significantly affects patients’ quality of life and represents a high economic burden for health systems. Given the lack of safe and effective treatments for PD, drug repositioning seeks to offer new medication alternatives, reducing research time and costs compared...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-09-01
|
| Series: | Journal of Nanobiotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12951-022-01612-5 |
| _version_ | 1811267423070846976 |
|---|---|
| author | Héctor Hernández-Parra Hernán Cortés José Arturo Avalos-Fuentes María Del Prado-Audelo Benjamín Florán Gerardo Leyva-Gómez Javad Sharifi-Rad William C. Cho |
| author_facet | Héctor Hernández-Parra Hernán Cortés José Arturo Avalos-Fuentes María Del Prado-Audelo Benjamín Florán Gerardo Leyva-Gómez Javad Sharifi-Rad William C. Cho |
| author_sort | Héctor Hernández-Parra |
| collection | DOAJ |
| description | Abstract Parkinson’s disease (PD) significantly affects patients’ quality of life and represents a high economic burden for health systems. Given the lack of safe and effective treatments for PD, drug repositioning seeks to offer new medication alternatives, reducing research time and costs compared to the traditional drug development strategy. This review aimed to collect evidence of drugs proposed as candidates to be reused in PD and identify those with the potential to be reformulated into nanocarriers to optimize future repositioning trials. We conducted a detailed search in PubMed, Web of Science, and Scopus from January 2015 at the end of 2021, with the descriptors “Parkinson’s disease” and “drug repositioning” or “drug repurposing”. We identified 28 drugs as potential candidates, and six of them were found in repositioning clinical trials for PD. However, a limitation of many of these drugs to achieve therapeutic success is their inability to cross the blood–brain barrier (BBB), as is the case with nilotinib, which has shown promising outcomes in clinical trials. We suggest reformulating these drugs in biodegradable nanoparticles (NPs) based on lipids and polymers to perform future trials. As a complementary strategy, we propose functionalizing the NPs surface by adding materials to the surface layer. Among other advantages, functionalization can promote efficient crossing through the BBB and improve the affinity of NPs towards certain brain regions. The main parameters to consider for the design of NPs targeting the central nervous system are highlighted, such as size, PDI, morphology, drug load, and Z potential. Finally, current advances in the use of NPs for Parkinson's disease are cited. |
| first_indexed | 2024-04-12T21:02:16Z |
| format | Article |
| id | doaj.art-3d1de16a2ecc41eb94b650f642489bf7 |
| institution | Directory Open Access Journal |
| issn | 1477-3155 |
| language | English |
| last_indexed | 2024-04-12T21:02:16Z |
| publishDate | 2022-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Nanobiotechnology |
| spelling | doaj.art-3d1de16a2ecc41eb94b650f642489bf72022-12-22T03:16:48ZengBMCJournal of Nanobiotechnology1477-31552022-09-0120112310.1186/s12951-022-01612-5Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimizationHéctor Hernández-Parra0Hernán Cortés1José Arturo Avalos-Fuentes2María Del Prado-Audelo3Benjamín Florán4Gerardo Leyva-Gómez5Javad Sharifi-Rad6William C. Cho7Departamento de Farmacología, Centro de Investigación Y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN)Laboratorio de Medicina Genómica, Departamento de Genómica, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra IbarraDepartamento de Fisiología, Biofísica & Neurociencias, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN)Escuela de Ingeniería Y Ciencias, Tecnologico de MonterreyDepartamento de Fisiología, Biofísica & Neurociencias, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN)Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de MéxicoFacultad de Medicina, Universidad del AzuayDepartment of Clinical Oncology, Queen Elizabeth HospitalAbstract Parkinson’s disease (PD) significantly affects patients’ quality of life and represents a high economic burden for health systems. Given the lack of safe and effective treatments for PD, drug repositioning seeks to offer new medication alternatives, reducing research time and costs compared to the traditional drug development strategy. This review aimed to collect evidence of drugs proposed as candidates to be reused in PD and identify those with the potential to be reformulated into nanocarriers to optimize future repositioning trials. We conducted a detailed search in PubMed, Web of Science, and Scopus from January 2015 at the end of 2021, with the descriptors “Parkinson’s disease” and “drug repositioning” or “drug repurposing”. We identified 28 drugs as potential candidates, and six of them were found in repositioning clinical trials for PD. However, a limitation of many of these drugs to achieve therapeutic success is their inability to cross the blood–brain barrier (BBB), as is the case with nilotinib, which has shown promising outcomes in clinical trials. We suggest reformulating these drugs in biodegradable nanoparticles (NPs) based on lipids and polymers to perform future trials. As a complementary strategy, we propose functionalizing the NPs surface by adding materials to the surface layer. Among other advantages, functionalization can promote efficient crossing through the BBB and improve the affinity of NPs towards certain brain regions. The main parameters to consider for the design of NPs targeting the central nervous system are highlighted, such as size, PDI, morphology, drug load, and Z potential. Finally, current advances in the use of NPs for Parkinson's disease are cited.https://doi.org/10.1186/s12951-022-01612-5Drug repositioningDrug repurposingParkinson’s diseaseNanoparticlesNanocarriersPharmaceutical nanotechnology |
| spellingShingle | Héctor Hernández-Parra Hernán Cortés José Arturo Avalos-Fuentes María Del Prado-Audelo Benjamín Florán Gerardo Leyva-Gómez Javad Sharifi-Rad William C. Cho Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization Journal of Nanobiotechnology Drug repositioning Drug repurposing Parkinson’s disease Nanoparticles Nanocarriers Pharmaceutical nanotechnology |
| title | Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization |
| title_full | Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization |
| title_fullStr | Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization |
| title_full_unstemmed | Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization |
| title_short | Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization |
| title_sort | repositioning of drugs for parkinson s disease and pharmaceutical nanotechnology tools for their optimization |
| topic | Drug repositioning Drug repurposing Parkinson’s disease Nanoparticles Nanocarriers Pharmaceutical nanotechnology |
| url | https://doi.org/10.1186/s12951-022-01612-5 |
| work_keys_str_mv | AT hectorhernandezparra repositioningofdrugsforparkinsonsdiseaseandpharmaceuticalnanotechnologytoolsfortheiroptimization AT hernancortes repositioningofdrugsforparkinsonsdiseaseandpharmaceuticalnanotechnologytoolsfortheiroptimization AT josearturoavalosfuentes repositioningofdrugsforparkinsonsdiseaseandpharmaceuticalnanotechnologytoolsfortheiroptimization AT mariadelpradoaudelo repositioningofdrugsforparkinsonsdiseaseandpharmaceuticalnanotechnologytoolsfortheiroptimization AT benjaminfloran repositioningofdrugsforparkinsonsdiseaseandpharmaceuticalnanotechnologytoolsfortheiroptimization AT gerardoleyvagomez repositioningofdrugsforparkinsonsdiseaseandpharmaceuticalnanotechnologytoolsfortheiroptimization AT javadsharifirad repositioningofdrugsforparkinsonsdiseaseandpharmaceuticalnanotechnologytoolsfortheiroptimization AT williamccho repositioningofdrugsforparkinsonsdiseaseandpharmaceuticalnanotechnologytoolsfortheiroptimization |